Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Aurobindo Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹1,552.40
High
₹1,585.30
Price Summary
| Previous Close | ₹1,574.30 |
|---|---|
| Day's Range | ₹1,552.40 - ₹1,585.30 |
| Open | ₹1,555.20 |
| 52 Week Range | ₹1,016.10 - ₹1,565.00 |
| Volume | 18,09,270 |
| Market Cap | ₹0.09 |
| Previous Close | ₹1,572.25 |
|---|---|
| Day's Range | ₹1,552.70 - ₹1,585.55 |
| Open | ₹1,563.15 |
| 52 Week Range | ₹1,017.00 - ₹1,564.70 |
| Volume | 43,003 |
| Market Cap | ₹0.09 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 28,483.34 |
|---|---|
| Market Cap (₹ in Mn) | 0.09 |
| Dividend Yield(%) | 0.26 |
| Price/Earning (TTM) | 25.53 |
| TTM EPS (₹) | 60.91 |
| P/E Ratio | 19.32 |
| Book Value(₹) | 2.36 |
| PAT Margin (%) | 5.48 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.39 |
| Trade Value ( ₹ in Lacs) | 676.11 |
|---|---|
| Market Cap (₹ in Mn) | 0.09 |
| Dividend Yield(%) | 0.26 |
| Price/Earning (TTM) | 25.53 |
| TTM EPS (₹) | 60.91 |
| P/E Ratio | 19.32 |
| Book Value(₹) | 2.36 |
| PAT Margin (%) | 5.48 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.39 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 317237.3 | 83821.2 |
| Expenses | N/A | N/A |
| PBT | 50662.9 | 13350.9 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 34835.7 | 9028.3 |
About Aurobindo Pharma Ltd.
| Founded | 1986 |
|---|---|
| Managing Director | K Nityananda Reddy |
| NSE Symbol | AUROPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,792.16 | 1,883.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,151.98 | 6,662.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,914.73 | 4,634.50 | 3,171.90 - 3,171.90 |
| Apollo Hospitals Enterprise Ltd. | 1,23,557.75 | 8,652.35 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,353.96 | 1,479.85 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,12,681.23 | 1,383.20 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,875.05 | 1,116.00 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,09,280.68 | 1,150.05 | 903.00 - 903.00 |
| Lupin Ltd. | 1,07,090.72 | 2,386.70 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,632.12 | 2,514.10 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Aurobindo Pharma informs about press release
Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with receipt of approval by Aurobindo Pharma USA, Inc. (‘Aurobindo USA’), a wholly owned subsidiary of the Company from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (‘Lannett’).
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) conducted a PAI at Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the Company), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, from June 10, 2026, to June 19, 2026. The inspection concluded with 5 observations and will be responded to within the stipulated time. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. The company will keep the stock exchanges informed if there is any further information relating to the above in the future. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure’.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about disclosure
Aurobindo Pharma informs about analyst meet
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva®, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Aurobindo Pharma Ltd. is ₹1,574.30 as of 2026-06-29.
The market capitalisation of Aurobindo Pharma Ltd. is ₹89,468.39 as of 2026-06-25.
The 1-year return of Aurobindo Pharma Ltd. is 453.30% as of 2026-06-29.
The P/E ratio of Aurobindo Pharma Ltd. is 19.32 as of 2026-06-29.
The 52-week high and low of Aurobindo Pharma Ltd. are ₹1,565.00 and ₹1,016.10, respectively, as of 2026-06-29.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
